1-hour Post-load Hyperglycemia and Mild Cognitive Impairment
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03363516 |
Recruitment Status : Unknown
Verified December 2017 by Maria Perticone, University Magna Graecia.
Recruitment status was: Recruiting
First Posted : December 6, 2017
Last Update Posted : December 7, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Glucose Metabolism Disorders Mild Cognitive Impairment | Diagnostic Test: Cerebral 3 Tesla MRI |

Study Type : | Observational |
Estimated Enrollment : | 30 participants |
Observational Model: | Other |
Time Perspective: | Prospective |
Official Title: | Early Prediction of Mild Cognitive Impairment in Glucose Normotolerant Subjects With 1-hour Post-load Plasma Glucose >155 mg/dL |
Actual Study Start Date : | October 2016 |
Estimated Primary Completion Date : | September 2018 |
Estimated Study Completion Date : | September 2018 |
Group/Cohort | Intervention/treatment |
---|---|
Cases
Glucose normotolerant subjects with 1-h post-load plasma glucose >155 mg/dL
|
Diagnostic Test: Cerebral 3 Tesla MRI
Subjects will be examined using a 3 Tesla MR750 GE MRI scanner with an eight-channel head coil. All participants will undergo the same MRI protocol, including: whole-brain 3D T1-weighted spoiled gradient recalled (SPGR) (BRAVO, voxel size of 1 × 1 × 1 mm3), DTI (voxel size 2 × 2 × 2 mm3, 27 directions with gradients at a b-value of 1,000 s/mm2 and 4 b = 0 images) and conventional 2D T2-weighted,T2 (FLAIR) and T2 gradient echo.
Other Name: Neuropsychological evaluation |
Controls
Glucose normotolerant subjects with 1-h post-load plasma glucose <155 mg/dL
|
Diagnostic Test: Cerebral 3 Tesla MRI
Subjects will be examined using a 3 Tesla MR750 GE MRI scanner with an eight-channel head coil. All participants will undergo the same MRI protocol, including: whole-brain 3D T1-weighted spoiled gradient recalled (SPGR) (BRAVO, voxel size of 1 × 1 × 1 mm3), DTI (voxel size 2 × 2 × 2 mm3, 27 directions with gradients at a b-value of 1,000 s/mm2 and 4 b = 0 images) and conventional 2D T2-weighted,T2 (FLAIR) and T2 gradient echo.
Other Name: Neuropsychological evaluation |
- Evidence of early neuropsychological and/or cerebral morphological/functional alterations of MCI in cases [ Time Frame: 1 month after enrollment ]Neuropsychological tests will be administered to all the study participants. All subjects will undergo an accurate evaluation of all the major cerebral functions in order to detect early alterations suggestive of mild cognitive impairment. Furthermore, all subjects will undergo a cerebral magnetic resonance using a 3 Tesla MR750 GE MRI scanner with an eight-channel head coil. All participants will undergo the same MRI protocol, including: whole-brain 3D T1-weighted spoiled gradient recalled (SPGR) (BRAVO, voxel size of 1 × 1 × 1 mm3), DTI (voxel size 2 × 2 × 2 mm3, 27 directions with gradients at a b-value of 1,000 s/mm2 and 4 b = 0 images) and conventional 2D T2-weighted,T2 (FLAIR) and T2 gradient echo. This test will investigate possible morphological and functional alterations suggestive of early dementia/MCI.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 55 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Subjects of both sex aged 55 years or older
- Ability to give informed written consent
- Mini mental state evaluation (MMSE) >20 at visit 1
Exclusion Criteria:
- Diabetes mellitus
- Clinically evident dementia or cognitive impairment
- Previous diagnosis of any disease predisposing to the risk of cognitive impairment (eg.: arterial hypertension, lipid metabolism alterations, obesity)
- Liver cirrhosis
- Family history of dementia and/or cognitive impairment
- History of alcohol or drugs abuse
- Use of medications influencing glucose homeostasis or cognitive functions
- Contraindications to undergo cerebral 3T-MRI
- Previous transient ischemic attack or stroke
- History of malignancies

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03363516
Contact: Maria Perticone, Dr | 0039 320 8592076 | mariaperticone@hotmail.com |
Italy | |
University Magna Graecia of Catanzaro - Department of Medical and Surgical Sciences - Internal Medicine and Geriatrics Units | Recruiting |
Catanzaro, Italy, 88100 | |
Contact: Maria Perticone, Dr 0039 320 8592076 mariaperticone@hotmail.com | |
Sub-Investigator: Franco Arturi, Prof |
Principal Investigator: | Maria Perticone, Dr | University Magna Graecia of Catanzaro |
Responsible Party: | Maria Perticone, Principal Investigator, University Magna Graecia |
ClinicalTrials.gov Identifier: | NCT03363516 |
Other Study ID Numbers: |
UNICZ01 |
First Posted: | December 6, 2017 Key Record Dates |
Last Update Posted: | December 7, 2017 |
Last Verified: | December 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Metabolic Diseases Glucose Metabolism Disorders Cognitive Dysfunction |
Cognition Disorders Neurocognitive Disorders Mental Disorders |